Effect of Infant and Maternal Secretor Status on Rotavirus Vaccine Take-An Overview
Overview
Authors
Affiliations
Histo-blood group antigens, which are present on gut epithelial surfaces, function as receptors or attachment factors and mediate susceptibility to rotavirus infection. The major determinant for susceptibility is a functional FUT2 enzyme which mediates the presence of α-1,2 fucosylated blood group antigens in mucosa and secretions, yielding the secretor-positive phenotype. Secretors are more susceptible to infection with predominant rotavirus genotypes, as well as to the commonly used live rotavirus vaccines. Difference in susceptibility to the vaccines is one proposed factor for the varying degree of efficacy observed between countries. Besides infection susceptibility, secretor status has been found to modulate rotavirus specific antibody levels in adults, as well as composition of breastmilk in mothers and microbiota of the infant, which are other proposed factors affecting rotavirus vaccine take. Here, the known and possible effects of secretor status in both infant and mother on rotavirus vaccine take are reviewed and discussed.
Geographic disparities impacting oral vaccine performance: Observations and future directions.
Burke R, Ramani S, Lynch J, Cooper L, Cho H, Bandyopadhyay A Clin Exp Immunol. 2025; 219(1).
PMID: 39774633 PMC: 11773816. DOI: 10.1093/cei/uxae124.
Lee B, Kader M, Alam M, Dickson D, Harvey P, Colgate E Pathogens. 2024; 13(3).
PMID: 38535566 PMC: 10974866. DOI: 10.3390/pathogens13030223.
Chauwa A, Bosomprah S, Laban N, Phiri B, Chibuye M, Chilyabanyama O Vaccines (Basel). 2023; 11(8).
PMID: 37631871 PMC: 10458424. DOI: 10.3390/vaccines11081303.
Maternal Breast Milk Secretor Phenotype Does Not Affect Infant Susceptibility to Rotavirus Diarrhea.
Williams F, Kader M, Dickson D, Colgate E, Alam M, Haque R Open Forum Infect Dis. 2023; 10(6):ofad299.
PMID: 37333724 PMC: 10270652. DOI: 10.1093/ofid/ofad299.
Vaccinomics: A scoping review.
Dudley M, Gerber J, Budigan Ni H, Blunt M, Holroyd T, Carleton B Vaccine. 2023; 41(14):2357-2367.
PMID: 36803903 PMC: 10065969. DOI: 10.1016/j.vaccine.2023.02.009.